Comparative characterization of ILT5-reactive and -nonreactive patients
| Category . | ILT5-reactive (n = 13), no. (%) . | ILT5-nonreactive (n = 227), no. (%) . | P . |
|---|---|---|---|
| SC source | |||
| Peripheral SC | 10 (76.9) | 202 (89) | .19 |
| Bone marrow | 3 (23.1) | 40 (17.6) | .62 |
| Conditioning | |||
| Reduced | 2 (15.4) | 73 (32.2) | .21 |
| Myeloablative | 11 (84.6) | 154 (67.8) | .21 |
| Donor | |||
| SD | 6 (46.2) | 93 (41) | .71 |
| MUD | 7 (53.8) | 122 (53.7) | .99 |
| MMUD | 0 (0) | 12 (5.3) | .4 |
| Unknown | 0 (0) | 9 (4) | .47 |
| HLA mismatch | 1 (7.7) | 20 (8.8) | .89 |
| GVHD | |||
| Never | 4 (30.8) | 43 (19) | .3 |
| Relapse | 3 (23.1) | 28 (12.3) | .26 |
| Death | 0 (0) | 25 (11) | .21 |
| Malignancies | |||
| Lymphatic | 4 (30.8) | 47 (20.7) | .39 |
| Myeloid | 7 (53.8) | 127 (55.9) | .88 |
| Lymphomas | 2 (15.4) | 32 (14) | .9 |
| Other | 0 (0) | 13 (5.7) | .38 |
| Category . | ILT5-reactive (n = 13), no. (%) . | ILT5-nonreactive (n = 227), no. (%) . | P . |
|---|---|---|---|
| SC source | |||
| Peripheral SC | 10 (76.9) | 202 (89) | .19 |
| Bone marrow | 3 (23.1) | 40 (17.6) | .62 |
| Conditioning | |||
| Reduced | 2 (15.4) | 73 (32.2) | .21 |
| Myeloablative | 11 (84.6) | 154 (67.8) | .21 |
| Donor | |||
| SD | 6 (46.2) | 93 (41) | .71 |
| MUD | 7 (53.8) | 122 (53.7) | .99 |
| MMUD | 0 (0) | 12 (5.3) | .4 |
| Unknown | 0 (0) | 9 (4) | .47 |
| HLA mismatch | 1 (7.7) | 20 (8.8) | .89 |
| GVHD | |||
| Never | 4 (30.8) | 43 (19) | .3 |
| Relapse | 3 (23.1) | 28 (12.3) | .26 |
| Death | 0 (0) | 25 (11) | .21 |
| Malignancies | |||
| Lymphatic | 4 (30.8) | 47 (20.7) | .39 |
| Myeloid | 7 (53.8) | 127 (55.9) | .88 |
| Lymphomas | 2 (15.4) | 32 (14) | .9 |
| Other | 0 (0) | 13 (5.7) | .38 |
SC indicates stem cells; MUD, matched unrelated donor; and MMUD, mismatched unrelated donor.